Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
Farmers Insurance
Daiichi Sankyo

Generated: June 27, 2017

DrugPatentWatch Database Preview

NEXPLANON Drug Profile

« Back to Dashboard

What is the patent landscape for Nexplanon, and when can generic versions of Nexplanon launch?

Nexplanon is a drug marketed by Organon Usa Inc and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-four patent family members in thirty-one countries.

The generic ingredient in NEXPLANON is etonogestrel. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the etonogestrel profile page.

Summary for Tradename: NEXPLANON

Suppliers / Packagers: see list1
Bulk Api Vendors: see list19
Clinical Trials: see list14
Patent Applications: see list848
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NEXPLANON at DailyMed

Pharmacology for Tradename: NEXPLANON

Ingredient-typeProgesterone Congeners
Drug ClassProgestin
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon Usa Inc
IMPLANT;IMPLANTATION021529-002May 31, 2011RXYesYes8,888,745► SubscribeY ► Subscribe
Organon Usa Inc
IMPLANT;IMPLANTATION021529-002May 31, 2011RXYesYes8,722,037► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NEXPLANON

Country Document Number Estimated Expiration
Peru00222006► Subscribe
Russian Federation2384347► Subscribe
South Africa200607602► Subscribe
Canada2593848► Subscribe
China1953770► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: NEXPLANON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
80027Netherlands► SubscribePRODUCT NAME: ETONOGESTREL; REGISTRATION NO/DATE: RVG 21168 19980825
C/GB99/044United Kingdom► SubscribePRODUCT NAME: ETONOGESTREL; REGISTERED: NL RGV21168 19980825; UK 00065/0161 19990609
/1999Austria► SubscribePRODUCT NAME: ETONOGESTREL; NAT. REGISTRATION NO/DATE: 1-22964 19990330; FIRST REGISTRATION: NL 21168 19980825
9C0041Belgium► SubscribePRODUCT NAME: ETONOGESTREL; NATL. REGISTRATION NO/DATE: 52 IS 296 F 14 19990531; FIRST REGISTRATION: NL RVG 21168 19980825
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
US Department of Justice
Argus Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus